CHINA PHARMA HOLDINGS INC

NYSE: CPHI (China Pharma Holdings, Inc.)

最近更新时间: 23 Jun, 6:45PM

1.68

-0.07 (-3.72%)

前收盘价格 1.75
收盘价格 1.66
成交量 161,663
平均成交量 (3个月) 108,516
市值 5,480,160
价格/销量 (P/S) 1.22
股市价格/股市净资产 (P/B) 0.940
52周波幅
1.20 (-28%) — 3.40 (102%)
利润日期 14 May 2021
营业毛利率 -106.30%
营业利益率 (TTM) -66.76%
稀释每股收益 (EPS TTM) -2.22
季度收入增长率 (YOY) -17.10%
总债务/股东权益 (D/E MRQ) 50.31%
流动比率 (MRQ) 0.560
资产报酬率 (ROA TTM) -18.22%
股东权益报酬率 (ROE TTM) -59.83%

市场趋势

短期 中期
行业 Drug Manufacturers - Specialty & Generic (US) 看涨 混合的
Drug Manufacturers - Specialty & Generic (全球的) 看涨 混合的
股票 China Pharma Holdings, Inc. - -

AIStockmoo 评分

0.6
分析师共识 2.0
内部交易活动 NA
价格波动 -2.0
技术平均移动指标 5.0
技术振荡指标 -2.5
平均 0.63

相关股票

股票 市值 DY P/E(TTM) P/B
CPHI 5 M - - 0.940
ZOM 98 M - - 0.520
YCBD 4 M - 0.922 0.740
ZTS 53 B 1.19% 20.34 9.64
TAK 48 B 4.61% 204.29 0.960
HLN 44 B 1.18% 22.51 2.04

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. The company also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. The company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

部门 Healthcare
行业 Drug Manufacturers - Specialty & Generic
内部持股比例 21.07%
机构持股比例 1.04%

所有权

姓名 日期 持有股份
First Community Trust Na 31 Mar 2025 0

该时间范围内无数据。

该时间范围内无数据。

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票